The global viral conjunctivitis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The market is projected to show substantial growth owing to the high number of people suffering from viral conjunctivitis as well as eye-related allergies followed by the easier availability of the necessary treatment across the globe. Although the disease is very common, treatment for it is easily available globally. Generally, viral conjunctivitis is self diagnosable and there is the minimum need of undergoing any diagnostic test for it.
Emerging economies such as India also witnessed a high prevalence of the disease. According to an article published by the journal, Clinical Epidemiology and Global Health, it was discovered that during the year 2019, the prevalence of allergic conjunctivitis was around 12.22% and the number of men suffering from this disease is higher than that of women in India. The epidemiology of the disease is similar in other Asian countries such as China. Hence, due to the high prevalence of the disease, the market is projected to have a steady growth during the forecast period. Furthermore, some key players operating in the market include AbbVie Inc., Takeda Pharmaceutical Co. Ltd., and Bausch Health Co. Inc., among others.
Market Coverage
Competitive Landscape: AbbVie Inc., Takeda Pharmaceutical Co. Ltd., and Bausch Health Co. Inc., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Viral Conjunctivitis Drugs Market by Segment
By Drug Class
• Artificial tears
• Decongestants
• Anti-histamines
• NSAIDS
• Anti-Viral drugs
• Steroids
• Antibiotics
By Virus Type
• Adenovirus
• Enterovirus
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Viral Conjunctivitis Drugs Market by Region
North America
Europe
Asia-Pacific
Rest of the World